138 related articles for article (PubMed ID: 9803006)
1. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer . preliminary results and therapeutic implications.
Mydlo JH; Kral JG; Volpe M; Axotis C; Macchia RJ; Pertschuk LP
Eur Urol; 1998; 34(5):426-32. PubMed ID: 9803006
[TBL] [Abstract][Full Text] [Related]
2. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
Krupski T; Petroni GR; Frierson HF; Theodorescu JU
Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.
Grossfeld GD; Carroll PR; Lindeman N; Meng M; Groshen S; Feng AC; Hawes D; Cote RJ
Urology; 2002 Jan; 59(1):97-102. PubMed ID: 11796289
[TBL] [Abstract][Full Text] [Related]
4. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer.
Revelos K; Petraki C; Scorilas A; Stefanakis S; Malovrouvas D; Alevizopoulos N; Kanellis G; Halapas A; Koutsilieris M
Anticancer Res; 2007; 27(5B):3651-60. PubMed ID: 17972531
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.
Ricciardelli C; Jackson MW; Choong CS; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
Prostate; 2008 Jun; 68(8):830-8. PubMed ID: 18324648
[TBL] [Abstract][Full Text] [Related]
6. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
7. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.
Silberman MA; Partin AW; Veltri RW; Epstein JI
Cancer; 1997 Feb; 79(4):772-9. PubMed ID: 9024715
[TBL] [Abstract][Full Text] [Related]
8. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
[TBL] [Abstract][Full Text] [Related]
13. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31.
de la Taille A; Katz AE; Bagiella E; Buttyan R; Sharir S; Olsson CA; Burchardt T; Ennis RD; Rubin MA
Am J Clin Pathol; 2000 Apr; 113(4):555-62. PubMed ID: 10761458
[TBL] [Abstract][Full Text] [Related]
14. The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma.
Fonseca GN; Srougi M; Leite KR; Nesrallah LJ; Ortiz V
Sao Paulo Med J; 2004 May; 122(3):124-7. PubMed ID: 15448811
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
16. Microvessel density in prostate carcinoma.
Bono AV; Celato N; Cova V; Salvadore M; Chinetti S; Novario R
Prostate Cancer Prostatic Dis; 2002; 5(2):123-7. PubMed ID: 12497001
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between HER-2/neu over-expression and androgen independent prostate cancer].
Bai Q; Chen F; Qi J; Chen JH; Wang YX
Zhonghua Nan Ke Xue; 2007 May; 13(5):414-6. PubMed ID: 17569256
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
Qiu YQ; Leuschner I; Braun PM
Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
20. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
